ImmunityBio, Inc. , a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases.
Immunitybio stock last closed at $7.38, up 0% from the previous day, and has increased 119.64% in one year. It has overperformed other stocks in the Biotechnology industry by 1.59 percentage points. Immunitybio stock is currently +303.28% from its 52-week low of $1.83, and -40.63% from its 52-week high of $12.43.
As of Mar 27, 2026, there are 1.03B IBRX shares outstanding. The market cap of IBRX is $7.59B. In the last 24 hours, 14.39M IBRX shares were traded.
How to Buy Immunitybio Stock
Wondering how to invest in Immunitybio stock? Here's how.
Decide where to buy Immunitybio stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you determine where to buy Immunitybio stock.
Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
Deposit money your brokerage account: Select your payment method and add your details.
Analyze Immunitybio stock: The Immunitybio ticker symbol is IBRX. Is Immunitybio stock a good investment? Should you buy shares of IBRX? How do IBRX's underlying business fundamentals look? Do top analysts think Immunitybio is a good buy? Why has IBRX's stock price moved recently? (Hint: Our stock research website can help you figure out if IBRX is a good stock to buy).
Place your IBRX purchase: Decide if you will purchase IBRX shares at the current market price or use a limit order to purchase IBRX stock at a specific price.
Get key alerts regarding your investment in IBRX: Create a watchlist to keep tabs on your position in Immunitybio stock.
Step 1: Decide where to buy Immunitybio stock
You will need a brokerage account to access the NASDAQ market and buy IBRX shares.
A brokerage account is an investment account that enables you to buy and sell a variety of financial instruments, including stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
In our opinion, eToro is the best stock brokerage. Here's why:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to world markets: From Technology to Financial Services, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by creating an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've selected your brokerage, you'll need to fill out some personal info so you can buy IBRX stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Analyze Immunitybio stock
Once you have decided on the best place to buy Immunitybio stock, it's crucial to analyze their stock before you buy, so you truly comprehend the risk and upside.
Immunitybio Numbers
IBRX Price
$7.38
1w %
-12.87%
1y %
119.64%
5y %
-70.07%
P/E
-19.42x
P/B
-15.16x
P/S
60x
PEG
N/A
Revenue
$113.29M
Earnings
-$351.40M
Fore. Rev. Growth
115.48%
Fore. Earn. Growth
N/A
Market Cap
$7.59B
Next Earnings
May 7, 2026
Next Dividend
N/A
IBRX Fundamentals
WallStreetZen was designed to help everyday investors perform more in-depth fundamental analysis.
There are more short-term assets than short-term liabilities on the IBRX balance sheet.
IBRX has $242.82M in cash and short term investments. This is sufficient to cover its annual cash burn of $309.19M.
Negative Health Checks:
IBRX profit margin has gone up by 24.95 percentage points in the past year, but the company is still unprofitable.
IBRX has cash burn of 309188000. It does not have sufficient cash and short-term investments to cover this.
There are more long-term liabilities than short-term assets on the IBRX balance sheet.
IBRX debt to equity ratio of -2 is negative.
Total IBRX debt is still negative.
Do Wall Street analysts think it's a good time to buy IBRX stock
Out of 7 Equities analysts who give forecasts on IBRX, the consensus analyst rating on IBRX is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Most Recent IBRX Analyst Recommendations
Joseph Catanzaro, a bottom 18% analyst from Piper Sandler maintains IBRX with a strong buy rating and raises their IBRX price target from $5.00 to $7.00, on Jan 20, 2026.
Piper Sandler's Joseph Catanzaro raised their price target on ImmunityBio (NASDAQ: IBRX) by 40% from $5 to $7 on 2026/01/20. The analyst maintained their Strong Buy rating on the stock.
Catanzaro contextualized their price target hike on ImmunityBio by highlighting that the company's U.S. ANKTIVA Net revenues gained 700% to $113M in 2025.
Looking ahead, the analyst reported that company management now projects $180M in FY 2026.
Looking further ahead and based on strong interim data, Piper Sandler is confident that positive QUILT-2.005 data in Q4 2026 will lead to ANKTIVA label expansion in 2027, Catanzaro added.
Kelly Shi, a top 17% analyst from Jefferies maintains IBRX with a strong buy rating and raises their IBRX price target from $8.00 to $9.00, on Dec 12, 2025.
Last year, IBRX revenue was $113.29M. In the last 5 year, IBRX's revenue has grown by 184.76% per year. This was faster than the Biotechnology industry average of 29%.
No, Immunitybio doesn't provide an income stream by paying out dividends.
What do other traders have to say about IBRX?
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Place your IBRX purchase
There are two main types of orders:
Market order: A market order is an order to buy or sell a security at the best price on the market. Market orders are mostly fine for most investors.
Limit order: A limit order allows you to buy or sell a security at a specific price (or better). If you want to ensure you're buying or selling at a given dollar amount limit, use a limit order.
Click the Open button and your broker will execute your order.
If you require additional info about buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Immunitybio share?
As of Mar 27, 2026, it costs $7.38 to buy one share of Immunitybio stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $3, you can buy 0.407 shares of IBRX.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.